A systematic review of treatments for bullous pemphigoid

被引:35
作者
Khumalo, NP [1 ]
Murrell, DF
Wojnarowska, F
Kirtschig, G
机构
[1] Groote Schuur Hosp, Dept Dermatol, ZA-7925 Cape Town, South Africa
[2] Churchill Hosp, Dept Dermatol, Oxford OX3 7LJ, England
[3] Univ New S Wales, St George Hosp, Sydney, NSW, Australia
[4] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
关键词
D O I
10.1001/archderm.138.3.385
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To assess the effectiveness of treatments for bullous pemphigoid. Methods: The Cochrane Library search strategy was used to identify randomized controlled trials from MEDLINE and EMBASE, from their inception to September 30, 2001. All randomized controlled trials on interventions for bullous pemphigoid, confirmed by immunofluorescence studies, were included. Results: We found 6 randomized controlled trials with a total of 293 patients. Two trials, one comparing prednisolone, 0.75 mg/kg per day, with prednisolone, 1.25 mg/kg per day, and the other comparing methylprednisolone with prednisolone, did not find any significant difference in effectiveness. The higher dose of prednisolone, however, was associated with more severe adverse effects. Combination treatments of prednisone with azathioprine in one trial and of prednisolone With plasma exchange in another were useful in halving the corticosteroid dose required (mean SD, 0.52 +/- 0.28 mg/kg in the plasma exchange-treated group vs 0.97 +/- 0.33 mg/kg in the prednisolone only-treated group). However, a fifth trial, including all 3 treatment groups (prednisolone alone, prednisolone and azathioprine, and prednisolone and plasma exchange), failed to confirm the benefit of combination treatment over prednisolone alone. A trial of 20 patients, comparing prednisone with tetracycline and niacinamide, found no statistically significant difference in response between the 2 groups, but the prednisone-treated group had more serious adverse effects. Conclusions: There is inadequate evidence for a recommendation of a specific treatment for bullous pemphigoid, and there is a need for larger randomized controlled trials with adequate power. Starting doses of prednisolone greater than 0.75 mg/kg per day do not seem to give additional benefit, and it seems that lower doses may be adequate for disease control. The effectiveness of the addition of plasma exchange or azathioprine to corticosteroids has not been established. Combination treatment with tetracycline and niacinamide seems useful, although this needs further validation.
引用
收藏
页码:385 / 389
页数:5
相关论文
共 20 条
[1]  
BERNARD P, 2000, J EUR ACAD DERMATOL, V14, P8
[2]   AZATHIOPRINE PLUS PREDNISONE IN TREATMENT OF PEMPHIGOID [J].
BURTON, JL ;
HARMAN, RRM ;
PEACHEY, RDG ;
WARIN, RP .
BRITISH MEDICAL JOURNAL, 1978, 2 (6146) :1190-1191
[3]  
DRENO B, 1993, ANN DERMATOL VENER, V120, P518
[4]  
ETIENNE SD, 1990, ANN MED INTERNE, V141, P507
[5]   RELATIVE AND ABSOLUTE BIOAVAILABILITY OF PREDNISONE AND PREDNISOLONE AFTER SEPARATE ORAL AND INTRAVENOUS DOSES [J].
FERRY, JJ ;
HORVATH, AM ;
BEKERSKY, I ;
HEATH, EC ;
RYAN, CF ;
COLBURN, WA .
JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (01) :81-87
[6]   NICOTINAMIDE AND TETRACYCLINE THERAPY OF BULLOUS PEMPHIGOID [J].
FIVENSON, DP ;
BRENEMAN, DL ;
ROSAN, GB ;
HERSH, CS ;
CARDONE, S ;
MUTASIM, D .
ARCHIVES OF DERMATOLOGY, 1994, 130 (06) :753-758
[7]   BIOAVAILABILITY AND REVERSIBLE METABOLISM OF PREDNISONE AND PREDNISOLONE IN MAN [J].
GARG, V ;
JUSKO, WJ .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1994, 15 (02) :163-172
[8]   CONTROLLED TRIAL OF AZATHIOPRINE AND PLASMA-EXCHANGE IN ADDITION TO PREDNISOLONE IN THE TREATMENT OF BULLOUS PEMPHIGOID [J].
GUILLAUME, JC ;
VAILLANT, L ;
BERNARD, P ;
PICARD, C ;
PROST, C ;
LABEILLE, B ;
GUILLOT, B ;
FOLDESPAUWELS, C ;
PRIGENT, F ;
JOLY, P ;
CORDOLIANI, F ;
SALAGNAC, V ;
MACHET, L ;
ALDIGIER, JC ;
CRICKX, B ;
ROUJEAU, JC .
ARCHIVES OF DERMATOLOGY, 1993, 129 (01) :49-53
[9]  
Kamada AK, 1997, PHARMACOTHERAPY, V17, P353
[10]  
KHURNALO NP, 2000, COCHRANE REV CD ROM